ABBV-291
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkin's Lymphoma
Conditions
Non-Hodgkin's Lymphoma
Trial Timeline
Jan 16, 2025 → Nov 1, 2031
NCT ID
NCT06667687About ABBV-291
ABBV-291 is a phase 1 stage product being developed by AbbVie for Non-Hodgkin's Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06667687. Target conditions include Non-Hodgkin's Lymphoma.
What happened to similar drugs?
6 of 20 similar drugs in Non-Hodgkin's Lymphoma were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06667687 | Phase 1 | Recruiting |
Competing Products
20 competing products in Non-Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 35 |
| Tazemetostat | Eisai | Phase 2 | 35 |
| ONTAK | Eisai | Phase 2 | 35 |
| Tazemetostat | Eisai | Phase 1 | 29 |
| ME-401 | Kyowa Kirin | Phase 1 | 29 |
| ME-401 | Kyowa Kirin | Phase 2 | 39 |
| gemcitabine | Eli Lilly | Phase 2 | 27 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 35 |
| LY317615 | Eli Lilly | Phase 2 | 35 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 36 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 40 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 25 |
| SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 29 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 21 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 21 |
| ABT-199 + Rituximab + Bendamustine | AbbVie | Phase 1 | 29 |
| ABT-199 | AbbVie | Phase 1 | 29 |
| Avelumab | Merck | Phase 1 | 33 |
| Pembrolizumab + Flt3L + Poly ICLC | Merck | Phase 1/2 | 28 |